Seagen Investor
Seagen is a clinical-stage biotechnology company dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.
Technology:
Cell_Therapies
Headquarters:
Bothell, Washington, United States
Founded Date:
1998-01-01
Employees Number:
1001-5000
Number Of Exits:
2
Investors Number:
4
Total Funding:
1739000000
Estimated Revenue:
$1B to $10B
Last Funding Date:
2020-09-14
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership